Affinity Asset Advisors, LLC Mersana Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.0 - $4.45 $466,000 - $1.04 Million	-233,000 Reduced 23.3%	767,000 $1.54 Million
Q4 2023 Feb 13, 2024	SELL	$1.11 - $2.34 $2.05 Million - $4.33 Million	-1,850,000 Reduced 64.91%	1,000,000 $2.32 Million
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $3.02 Million - $11.1 Million	2,850,000 New	2,850,000 $3.62 Million
Q3 2021 Nov 12, 2021	SELL	$8.56 - $14.47 $727,600 - $1.23 Million	-85,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$15.31 - $26.52 $535,850 - $928,200	35,000 Added 70.0%	85,000 $1.38 Million
Q4 2020 Feb 12, 2021	BUY	$16.84 - $27.59 $842,000 - $1.38 Million	50,000 New	50,000 $1.33 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $157M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.